These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 11346861)

  • 1. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
    Major PP; Coleman RE
    Semin Oncol; 2001 Apr; 28(2 Suppl 6):17-24. PubMed ID: 11346861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.
    Major P; Lortholary A; Hon J; Abdi E; Mills G; Menssen HD; Yunus F; Bell R; Body J; Quebe-Fehling E; Seaman J
    J Clin Oncol; 2001 Jan; 19(2):558-67. PubMed ID: 11208851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
    Major P
    Oncologist; 2002; 7(6):481-91. PubMed ID: 12490736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy.
    Wellington K; Goa KL
    Drugs; 2003; 63(4):417-37. PubMed ID: 12558465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid: a new parenteral bisphosphonate.
    Li EC; Davis LE
    Clin Ther; 2003 Nov; 25(11):2669-708. PubMed ID: 14693298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials.
    Berenson JR
    Semin Oncol; 2001 Apr; 28(2 Suppl 6):25-34. PubMed ID: 11346862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
    Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S
    Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
    Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
    Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and convenience of a 15-minute infusion of zoledronic acid.
    Berenson J; Hirschberg R
    Oncologist; 2004; 9(3):319-29. PubMed ID: 15169987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid.
    Maxwell C; Swift R; Goode M; Doane L; Rogers M
    Clin J Oncol Nurs; 2003; 7(4):403-8. PubMed ID: 12929273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the biology and treatment of myeloma bone disease.
    Berenson JR
    Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S16-20. PubMed ID: 11757204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
    Berenson JR; Rosen LS; Howell A; Porter L; Coleman RE; Morley W; Dreicer R; Kuross SA; Lipton A; Seaman JJ
    Cancer; 2001 Apr; 91(7):1191-200. PubMed ID: 11283917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of bone metastases in breast cancer.
    Lipton A
    Curr Treat Options Oncol; 2005 Mar; 6(2):161-71. PubMed ID: 15717997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases.
    Coleman RE; Seaman JJ
    Semin Oncol; 2001 Apr; 28(2 Suppl 6):11-6. PubMed ID: 11346860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
    Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials.
    Coleman RE
    Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S25-31. PubMed ID: 12562048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid.
    Cheer SM; Noble S
    Drugs; 2001; 61(6):799-805; discussion 806. PubMed ID: 11398911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates: clinical experience.
    Coleman RE
    Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.